On February 26, 2026, the U.S. Food and Drug Administration (FDA) published a batch of draft product-specific guidances (PSGs) aimed at supporting generic drug development and streamlining Abbreviated New Drug Application (ANDA) approvals for pharmaceuticals. The update affects companies and teams involved in developing, submitting, or reviewing ANDAs, particularly for both complex and non-complex generic products.
Details of the Update
The FDA released new and revised draft PSGs that outline regulatory expectations for demonstrating therapeutic equivalence to reference listed drugs. The guidances cover 98 products, including those with no currently approved generics, and introduce new guidance for opioid use disorder treatments and oral semaglutide for cardiovascular risk reduction.
Several existing PSGs were revised, with updates affecting modified-release formulations and transdermal and topical systems, resulting in changes to study expectations such as alcohol dose dumping studies and sensitization testing. In addition, the FDA updated its online listing to include upcoming PSGs under development, along with anticipated publication dates to support development planning.
Why It Matters
These draft PSGs provide greater regulatory clarity on study design and data requirements for generic drug development, supporting digital alignment and planning efficiency for ANDA programs. By clarifying expectations across complex and non-complex products, the update aims to improve predictability while maintaining a neutral impact and minimal additional regulatory burden for industry stakeholders.
Who This Is Relevant For
This update is relevant for Regulatory Affairs, Quality Assurance, R&D, and Legal teams involved in generic drug development and ANDA submissions, particularly those working on complex formulations or products with evolving study requirements.
Next Steps
Companies should evaluate current and planned ANDA submissions against the newly published and revised PSGs to identify any gaps in study protocols or data packages. Where development programs may be affected, applicants may request teleconferences with the FDA under GDUFA III commitments. Ongoing monitoring of the FDA’s PSG listings is recommended to anticipate future guidance relevant to product portfolios.
As regulatory expectations for generics continue to evolve, staying ahead of draft and upcoming PSGs is critical for efficient development planning. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, helping teams track FDA guidance updates, assess impact on ANDA programs, and streamline compliance workflows across more than 160 countries. Learn more or book a demo now.
FAQs
What are FDA product-specific guidances (PSGs)?
FDA PSGs are guidance documents that outline recommended study designs and data requirements for demonstrating therapeutic equivalence in generic drug applications.
How many products are covered in the February 2026 draft PSG update?
The FDA’s draft update covers 98 products, including new and revised guidances.
Which types of generic products are most affected by this update?
The update particularly affects complex products, modified-release formulations, transdermal and topical systems, as well as products for opioid use disorder and oral semaglutide.
How can RegASK help teams manage FDA PSG updates?
RegASK helps regulatory and development teams track draft and finalized PSGs, assess their impact on ongoing ANDA programs, and coordinate regulatory workflows using AI-driven insights supported by experts in the loop.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
